Franz B. Humer, Ph.D. M.B.A., is the Executive Chairman of the Board of Directors at Neogene Therapeutics. Dr. Humer joined Hoffmann-La Roche in 1995 as a member of its Board and the head of its pharmaceuticals division, progressing to become Chairman and CEO in 2001, and between 2008 and 2014 the Chairman of Roche Holding Limited. Before joining Roche Group, he was the managing director of Glaxo Pharmaceuticals UK Ltd. was elected to the Board of Glaxo Holdings plc and progressed to be responsible for research, business development, manufacturing, commercial strategy, and all non-U.S. operations for 13 years. In 1973, Franz joined Schering-Plough Corporation, where he held various general management positions in Latin America and Europe. Dr. Humer also serves as Chairman of the Board of Directors of the International Centre for Missing & Exploited Children and Chairman of the Humer Foundation. He is also Chairman of PCI Services and an Advisor to Temasek Holdings and Letterone Healthcare. Franz joined the Board of Diageo in 2005, became Chairman in 2008 and retired in 2016. Franz earned a PhD in law from the University of Innsbruck and an MBA from INSEAD in Fontainbleau, France.